GC
EBS icon

Globeflex Capital’s Emergent Biosolutions EBS Stock Holding History

Globeflex Capital’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.02M Hold
241,298
– – 0.26% 109
2026
Q1 		$2M Hold
241,298
– – 0.3% 93
2025
Q4 		$2.98M Hold
241,298
– – 0.46% 73
2025
Q3 		$2.13M Buy
+241,298
New +$1.88M 0.33% 88
2021
Q3 		– Sell
-5,878
Closed -$370K – 467
2021
Q2 		$370K Sell
5,878
-9,580
-62% -$615K 0.07% 315
2021
Q1 		$1.44M Sell
15,458
-1,460
-9% -$150K 0.26% 122
2020
Q4 		$1.52M Buy
16,918
+159
+0.9% +$14.6K 0.32% 86
2020
Q3 		$1.73M Sell
16,759
-4,281
-20% -$461K 0.46% 50
2020
Q2 		$1.66M Sell
21,040
-178
-0.8% -$13.3K 0.42% 49
2020
Q1 		$1.23M Sell
21,218
-2,355
-10% -$136K 0.38% 69
2019
Q4 		$1.27M Hold
23,573
– – 0.24% 138
2019
Q3 		$1.23M Hold
23,573
– – 0.27% 113
2019
Q2 		$1.14M Sell
23,573
-27
-0.1% -$1.29K 0.24% 127
2019
Q1 		$1.19M Hold
23,600
– – 0.25% 123
2018
Q4 		$1.4M Buy
23,600
+2
+0% +$129 0.33% 92
2018
Q3 		$1.55M Sell
23,598
-396
-2% -$23.1K 0.31% 97
2018
Q2 		$1.21M Sell
23,994
-3,898
-14% -$203K 0.25% 141
2018
Q1 		$1.47M Buy
27,892
+20,968
+303% +$1.05M 0.31% 108
2017
Q4 		$322K Buy
+6,924
New +$291K 0.09% 272
2015
Q4 		– Sell
-27,125
Closed -$773K – 461
2015
Q3 		$773K Buy
+27,125
New +$894K 0.17% 223
2015
Q2 		– Sell
-89,151
Closed -$2.56M – 530
2015
Q1 		$2.56M Sell
89,151
-4,840
-5% -$139K 0.49% 42
2014
Q4 		$2.56M Sell
93,991
-25
-0% -$596 0.49% 46
2014
Q3 		$2M Sell
94,016
-3,769
-4% -$86.3K 0.23% 136
2014
Q2 		$2.2M Sell
97,785
-41
-0% -$955 0.24% 131
2014
Q1 		$2.47M Buy
97,826
+31,520
+48% +$796K 0.28% 120
2013
Q4 		$1.52M Sell
66,306
-5,425
-8% -$113K 0.18% 145
2013
Q3 		$1.37M Hold
71,731
– – 0.18% 163
2013
Q2 		$1.03M Buy
+71,731
New +$1.04M 0.14% 186

Other funds holding EBS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
OHA
Oak Hill Advisors New York $701M AUM 78.4% 1-Year Est. Return

Globeflex Capital's EBS Position: Q2 2026 in Review

Globeflex Capital held its Emergent Biosolutions (EBS) position steady in Q2 2026 at 241,298 shares worth $2.02M. The position accounts for 0.26% of the portfolio, ranked #109.

Globeflex Capital first reported a position in EBS in Q2 2013 and has held it in 28 quarters since. The position peaked at $2.98M in Q4 2025. 194 funds tracked by Wall St. Rank hold EBS as of Q2 2026.

  • Globeflex Capital held 241,298 shares of Emergent Biosolutions worth $2.02M as of Q2 2026.
  • Globeflex Capital left its Emergent Biosolutions share count unchanged in Q2 2026.
  • Emergent Biosolutions made up 0.26% of Globeflex Capital's portfolio in Q2 2026, its #109 holding.
  • Globeflex Capital first reported a position in Emergent Biosolutions in Q2 2013 and has held it in 28 quarters since.
  • Globeflex Capital's Emergent Biosolutions position peaked at $2.98M in Q4 2025.
  • 194 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q2 2026.

Based on Globeflex Capital's 13F filing for Q2 2026, filed 12 Aug 2026.